HBPK-002

HBPK-002 is a preclinical **oral small-molecule glucagon-like peptide 1 receptor agonist** being developed by **Hummsa Biotech** for metabolic and age-related diseases. Public sponsor materials describe it as a first-in-class, non-peptide GLP-1 receptor agonist intended to improve metabolic function, with claimed effects including enhancement of insulin sensitivity, glucose control, liver health markers, and potential regeneration of pancreatic beta cells. The company positions the program across multiple indications including type 1 diabetes, type 2 diabetes, obesity, MASLD/MASH, osteoporosis, and Alzheimer's disease, but as of the public-source evidence reviewed, HBPK-002 appears to remain in **preclinical development** and detailed peer-reviewed pharmacology, clinical data, formulation specifics, and manufacturing disclosures have not yet been identified.